

ONCOLOGÍA TRASLACIONAL

Ajani, JA; Abramov, M; Bondarenko, I; Shparyk, Y; Gorbunova, V; Hontsa, A; Otchenash, N; Alsina, M; Lazarev, S; Feliu, J; Elme, A; Esko, V; Abdalla, K; Verma, U; Benedetti, F; Aoyama, T; Mizuguchi, H; Makris, L; Rosati, G. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. ANNALS OF ONCOLOGY. 2017; 28(9):2142-2148.Article. IF -11,855

Almhanna, K; Wright, D; Mercade, TM; Laethem, JL; Gracian, AC; Guillen-Ponce, C; Faris, J; Lopez, CM; Hubner, RA; Bendell, J; Bols, A; Feliu, J; Starling, N; Enzinger, P; Mahalingham, D; Messersmith, W; Yang, HY; Fasanmade, A; Danaee, H; Kalebic, T. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. INVESTIGATIONAL NEW DRUGS. 2017; 35(5):634-641.Article. IF -3,484

Apellaniz-Ruiz, M; Tejero, H; Inglada-Perez, L; Sanchez-Barroso, L; Gutierrez-Gutierrez, G; Calvo, I; Castelo, B; Redondo, A; Garcia-Donas, J; Romero-Laorden, N; Sereno, M; Merino, M; Curras-Freixes, M; Montero-Conde, C; Mancikova, V; Avall-Lundqvist, E; Green, H; Al-Shahrour, F; Cascon, A; Robledo, M; Rodriguez-Antona, C. Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy. CLINICAL CANCER RESEARCH. 2017; 23(5):1227-1235.Article. IF -9,619

Aranda, E; Aparicio, J; Bilbao, JI; Alfonso, PG; Maurel, J; Rodriguez, J; Sangro, B; Vieitez, JM; Feliu, J. Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases. FUTURE ONCOLOGY. 2017; 13(23):2065-2082.Article. IF -2,131

Arija, JA; Perez-Valderrama, B; Sanchez, AR; Alvarez, JP; Marin, AP; Alonso, CM; Guzman, JCV; Parra, EMF; Diaz, EG; Gonzalez-Larriba, J; Garcia, JT; Lambea, J; Figueiras, MC; Vidal, MJM; Echaburu, JAV; Mazon, FJV; Ulazia, OE; Villar, MTA; Cassinello, J; Garcia, JMJ. SPAZO2 (SOGUG): Comparative effectiveness of everolimus (Ev) vs axitinib (Ax) as second-line after first-line pazopanib (1stPz) in metastatic renal carcinoma (mRC). ANNALS OF ONCOLOGY. 2017; 28:..Meeting Abstract. IF -11,855

Barriuso, J; Lamarca, A; Heredia, V; Guerra-Pastrian, L; Alvarez-Escola, C; Castell, J; Custodio, A; Miguel, M; Mendiola, M; Feliu, J. Integrative DNA methylome and miRNA transcriptome analysis for new biomarker discovery in entero-pancreatic neuroendocrine tumours (EP-NETS). ANNALS OF ONCOLOGY. 2017; 28:..Meeting Abstract. IF -11,855

Blank, CU; Larkin, J; Arance, AM; Hauschild, A; Queirolo, P; Del Vecchio, M; Ascierto, PA; Krajsova, I; Schachter, J; Neyns, B; Garbe, C; Sileni, VC; Mandala, M; Gogas, H; Espinosa, E; Hospers, GAP; Miller, WH; Robson, S; Makrutzki, M; Antic, V; Brown, MP. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. EUROPEAN JOURNAL OF CANCER. 2017; 79:176-184.Article. IF - 6,029

Boni, V; Garcia-Corbacho, J; Feliu, J; Wydmanski, J; Horvath, Z; Bondarenko, I; Irving, B; Will, M; de Vries, EGE; Thistlethwaite, F. The first-in-human, dose-finding PROCLAIM-CX-072 trial to assess the antitumor activity and tolerability of the probody therapeutic CX-072 as monotherapy and in combination with ipilimumab or vemurafenib in solid advanced tumors and lymphomas. ANNALS OF ONCOLOGY. 2017; 28:-.Meeting Abstract. IF -11,855

Calderon, C; Ferrando, PJ; Carmona-Bayonas, A; Lorenzo-Seva, U; Jara, C; Beato, C; Garcia, T; Ramchandani, A; Castelo, B; Munoz, MM; Garcia, S; Higuera, O; Mangas-Izquierdo, M; Jimenez-Fonseca, P. Validation of SDM-Q-Doc Questionnaire to measure shared decision-making physician's perspective in oncology practice. CLINICAL & TRANSLATIONAL ONCOLOGY. 2017; 19(11):1312-1319.Article. IF -2,353

Calderon, C; Ferrando, PJ; Lorenzo-Seva, U; Carmona-Bayonas, A; Jara, C; de la Pena, FA; Beato, C; Ramchandani, A; Garcia, T; Mangas-Izquierdo, M; Castelo, B; Donnay, O; Munoz, MD; de Castro, EM; Garcia, S; Ghanem, I; Mellen, T; Jimenez-Fonseca, P. Psychometric properties of Liverpool Stoicism Scale (LSS) in a cohort of patients with resected cancer in adjuvant treatment. ANALES DE PSICOLOGIA. 2017; 33(3):621-629.Article. IF -0,871

Carmona-Bayonas, A; Jimenez-Fonseca, P; Castanon, E; Ramchandani-Vaswani, A; Sanchez-Bayona, R; Custodio, A; Calvo-Temprano, D; Virizuela, JA. Chronic opioid therapy in long-term cancer survivors. CLINICAL & TRANSLATIONAL ONCOLOGY. 2017; 19(2):236-250.Article. IF -2,353

Carmona-Bayonas, A; Jimenez-Fonseca, P; Custodio, A; Grande, E; Capdevila, J; Lopez, C; Teule, A; Garcia-Carbonero, R. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors. CURRENT ONCOLOGY REPORTS. 2017; 19(11):-72.Review. IF -2,608

Carmona-Bayonas, A; Jimenez-Fonseca, P; Hernandez, R; Custodio, A; Cano, JM; Lacalle, A; Diaz-Guardamino, IE; Macias, I; Izquierdo, MM; Visa, L; Orra, EB; Azkarate, A; Vaswani, AR; de Castro, EM; Montes, AF; Longo, F; Bayona, RS; Limon, ML; Carnicero, AM; Plazas, JG. Treatment of advanced gastric cancer based on Lauren's histological: Real-world data from the AGAMEMON National Cancer Registry. ANNALS OF ONCOLOGY. 2017; 28:-.Meeting Abstract. IF -11,855

Cejas, P; Cavazza, A; Yandava, CN; Moreno, V; Horst, D; Moreno-Rubio, J; Burgos, E; Mendiola, M; Taing, L; Goel, A; Feliu, J; Shivdasani, RA. Transcriptional Regulator CNOT3 Defines an Aggressive Colorectal Cancer Subtype. *CANCER RESEARCH*. 2017; 77(3):766-779.Article. IF -9,112

Codony-Servat, J; Cuatrecasas, M; Asensio, E; Montironi, C; Martinez-Cardus, A; Marin-Aguilera, M; Horndler, C; Martinez-Balibrea, E; Rubini, M; Jares, P; Reig, O; Victoria, I; Gaba, L; Martin-Richard, M; Alonso, V; Escudero, P; Fernandez-Martos, C; Feliu, J; Mendez, JC; Mendez, M; Gallego, J; Salud, A; Rojo, F; Castells, A; Prat, A; Rosell, R; Garcia-Albeniz, X; Camps, J; Maurel, J. Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. *BRITISH JOURNAL OF CANCER*. 2017; 117(12):1777-1786.Article. IF -6,176

Crespo, G; Jimenez-Fonseca, P; Custodio, A; Lopez, C; Carmona-Bayonas, A; Alonso, V; Navarro, M; Aller, J; Sevilla, I; Grande, E; Gajate, P; Alonso-Gordoa, T; Matos, I; Capdevila, J; Nieto, B; Barriuso, J. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience. *FUTURE ONCOLOGY*. 2017; 13(7):615-624.Article. IF -2,131

Custodio, A; Carmona-Bayonas, A; Jimenez-Fonseca, P; Sanchez, ML; Viudez, A; Hernandez, R; Cano, JM; Echavarria, I; Pericay, C; Mangas, M; Visa, L; Buxo, E; Garcia, T; Palomo, AR; Mancenido, FA; Lacalle, A; Macias, I; Azkarate, A; Ramchandani, A; Montes, AF; Lopez, C; Longo, F; Bayona, RS; Limon, ML; Diaz-Serrano, A; Hurtado, A; Madero, R; Gomez, C; Gallego, J. Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab. *BRITISH JOURNAL OF CANCER*. 2017; 116(12):1526-1535.Article. IF -6,176

de Cedron, MG; Perez, RA; Sanchez-Martinez, R; Molina, S; Herranz, J; Feliu, J; Reglero, G; Enriquez, JA; de Molina, AR. MicroRNA-661 modulates redox and metabolic homeostasis in colon cancer. *MOLECULAR ONCOLOGY*. 2017; 11(12):1768-1787.Article. IF -5,314

de Velasco, G; Trilla-Fuertes, L; Gamez-Pozo, A; Urbanowicz, M; Ruiz-Ares, G; Sepulveda, JM; Prado-Vazquez, G; Arevalillo, JM; Zapater-Moros, A; Navarro, H; Lopez-Vacas, R; Manneh, R; Otero, I; Villacampa, F; Paramio, JM; Vara, JAF; Castellano, D. Urothelial cancer proteomics provides both prognostic and functional information. *SCIENTIFIC REPORTS*. 2017; 7:-15819.Article. IF -4,259

del Alba, AG; Arranz, JA; Puente, J; Mendez-Vidal, MJ; Gallardo, E; Grande, E; Perez-Valderrama, B; Gonzalez-Billalabeitia, E; Lazaro-Quintela, M; Pinto, A; Lainez, N; Piulats, JM; Esteban, E; Rey, JPM; Garcia, JA; Suarez, C. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. *CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY*. 2017; 113:171-190.Review. IF -4,971

Espinosa, E; Marquez-Rodas, I; Soria, A; Berrocal, A; Manzano, JL; Gonzalez-Cao, M; Martin-Algarra, S. Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM). ANNALS OF TRANSLATIONAL MEDICINE. 2017; 5(19):-389.Review. IF -NO TIENE

Estelles, DL; Puente, J; Medina, A; Mejorada, RL; Rivera, L; Pacheco, MI; Saez, MI; Rodriguez, JMP; Parra, EMF; Garcia, PB; Valderrama, BP; Diaz, EG; Villatoro, R; Barrera, RM; Estevez, SV; Marin, AP; Ibanez, JAC; Laorden, NR; Marcos, EC. PROSABI: Prospective multi-centre study of prognostic factors in castration resistant prostate cancer (CRPC) patients treated with abiraterone acetate (AA). ANNALS OF ONCOLOGY. 2017; 28:-.Meeting Abstract. IF -11,855

Feliu, J; de Corcuera, ID; Manzano, JL; Valladares-Ayerbes, M; Alcaide, J; Garcia, TG; Vera, R; Sastre, J. Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain. CLINICAL & TRANSLATIONAL ONCOLOGY. 2017; 19(4):498-507.Review. IF -2,353

Fonseca, PJ; Carmona-Bayonas, A; Hernandez, R; Custodio, A; Cano, JM; Lacalle, A; Echavarria, I; Macias, I; Mangas, M; Visa, L; Buxo, E; Mancenido, FA; Viudez, A; Pericay, C; Azkarate, A; Ramchandani, A; Lopez, C; de Castro, EM; Montes, AF; Longo, F; Bayona, RS; Limon, ML; Diaz-Serrano, A; Carnicero, AM; Arias, D; Cerda, P; Rivera, F; Vieitez, JM; Canovas, MS; Garrido, M; Gallego, J. Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry. BRITISH JOURNAL OF CANCER. 2017; 117(6):775-782.Article. IF -6,176

Gallego, A; Martinez, B; Espinosa, E; Ghanem, I; Ruiz-Gimenez, L; Garcia, T; Gonzalez, T; Castelo, B; Zamora, P; Redondo, A; Feliu, J. Long-term cancer survivors: Satisfaction with medical care and information received during the diagnosis and treatment of cancer. JOURNAL OF CLINICAL ONCOLOGY. 2017; 35:-.Meeting Abstract. IF -24,008

Gamez-Pozo, A; Trilla-Fuertes, L; Berges-Soria, J; Selevsek, N; Lopez-Vacas, R; Diaz-Almiron, M; Nanni, P; Arevalillo, JM; Navarro, H; Grossmann, J; Moreno, FG; Rioja, RG; Prado-Vazquez, G; Zapater-Moros, A; Main, P; Feliu, J; del Prado, PM; Zamora, P; Ciruelos, E; Espinosa, E; Vara, JAF. Functional proteomics outlines the complexity of breast cancer molecular subtypes. SCIENTIFIC REPORTS. 2017; 7:-10100.Article. IF -4,259

Gamez-Pozo, A; Trilla-Fuertes, L; Prado-Vazquez, G; Chiva, C; Lopez-Vacas, R; Nanni, P; Berges-Soria, J; Grossmann, J; Diaz-Almiron, M; Ciruelos, E; Sabido, E; Espinosa, E; Vara, JAF. Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics. PLOS ONE. 2017; 12(6):-e0178296.Article. IF -2,806

Garcia, AP; Berjon, A; Yebenes, L; Zamora, P; Mendez, JIS; Espinosa, E; Redondo, A; Mendiola, M; Hardisson, D. The EndoPredict gene-expression assay in clinical practice in ER-positive/HER2-negative primary invasive breast cancer: Comparison with standard clinicopathological parameters. VIRCHOWS ARCHIV. 2017; 471:S55-S55.Meeting Abstract. IF -2,848

Garcia, S; Calderon, C; Carmona-Bayonas, A; Beato, C; Castelo, B; Izquierdo, MM; Garcia, T; Rogado, J; Sanchez, CJ; Jimenez-Fonseca, P. Comparison between male vs female physician's communication style. PSYCHO-ONCOLOGY. 2017; 26:147-147.Meeting Abstract. IF -3,095

Garcia, S; Calderon, C; Jimenez-Fonseca, P; Anguera, G; Beato, C; Castelo, B; Izquierdo, MM; Garcia, T; Rogado, J; Sanchez, CJ. Cognitive functions, adjustment to cancer and psychological symptom in patients with resected cancer receiving chemotherapy. PSYCHO-ONCOLOGY. 2017; 26:112-112.Meeting Abstract. IF -3,095

Garcia-Corbacho, J; Spira, A; Boni, V; Feliu, J; Middleton, M; Burris, H; Weaver, AY; Will, M; Harding, J; Meric-Bernstam, F; Heinemann, V. PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors. ANNALS OF ONCOLOGY. 2017; 28:-.Meeting Abstract. IF -11,855

Gonzalez, A; Lluch, A; Aba, E; Albanell, J; Anton, A; Alvarez, I; Ayala, F; Barnadas, A; Calvo, L; Ciruelos, E; Cortes, J; de la Haba, J; Lopez-Vega, JM; Martinez, E; Munoz, M; Pelaez, I; Redondo, A; Rodriguez, A; Rodriguez, CA; Ruiz, A; Llombart, A. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM). CLINICAL & TRANSLATIONAL ONCOLOGY. 2017; 19(5):616-624.Article. IF -2,353

Gonzalez-Cao, M; Arance, A; Piulats, JM; Marquez-Rodas, I; Manzano, JL; Berrocal, A; Crespo, G; Rodriguez, D; Perez-Ruiz, E; Berciano, M; Soria, A; Castano, AG; Espinosa, E; Montagut, C; Alonso, L; Puertolas, T; Aguado, C; Royo, MA; Blanco, R; Rodriguez, JF; Munoz, E; Mut, P; Barron, F; Martin-Algarra, S. Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program. CLINICAL & TRANSLATIONAL ONCOLOGY. 2017; 19(6):761-768.Article. IF -2,353

Gonzalez-Cao, M; Berrocal, A; Puig, S; Karachaliou, N; De Matos-Arruda, L; Seoane, J; Escors, D; Alvarez, C; Vaque, JP; Prat, A; Wellbrock, C; Arozarena, I; Marquez-Rodas, I; Espinosa, E; Molina, MA; Puertolas, T; Juan-Otero, M; Malagrida, R; Jantus-Lewintre, E; Soriano, V; Arance, A; Manzano, JL; Lorigan, P; Gajewski, TF; Rosell, R; Martin-Algarra, S. Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). ANNALS OF TRANSLATIONAL MEDICINE. 2017; 5(19):-390.Article. IF -NO TIENE

Heredia, V; Mendiola, M; Ortiz, E; Bernabeu, D; Pozo-Kreiling, JJ; Miguel, M; Crespo, R; Berjon, A; Martinez-Marin, V; Redondo, A. AG-120, a novel IDH1 targeted molecule,

inhibits invasion and migration of chondrosarcoma cells in vitro. ANNALS OF ONCOLOGY. 2017; 28:-.Meeting Abstract. IF -11,855

Jimenez-Fonseca, P; Carmona-Bayonas, A; Lorenzo, MLS; Plazas, JG; Custodio, A; Hernandez, R; Garrido, M; Garcia, T; Echavarria, I; Cano, JM; Palomo, AR; Mangas, M; Declara, IM; Ramchandani, A; Visa, L; Viudez, A; Buxo, E; Diaz-Serrano, A; Lopez, C; Azkarate, A; Longo, F; Castanon, E; Bayona, RS; Pimentel, P; Limon, ML; Cerda, P; Llosa, RA; Serrano, R; Lobera, MPF; Alsina, M; Nuno, A; Gomez-Martin, C. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. GASTRIC CANCER. 2017; 20(3):465-474.Article. IF -5,454

Jimenez-Fonseca, P; Castano, A; Barrio, JJP; Alonso, V; Custodio, A; Marazuela, M; Llanos, M; Diaz, JA; Lopez, C; Alonso, T; Blanco, C; La Casta, A; Alvarez-Escola, C; Alcazar, V; Capdevila, J. Long-Term Outcomes and Prognostic Factors of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): An Update of a Large National Registry (RGETNE). NEUROENDOCRINOLOGY. 2017; 105():81-81.Meeting Abstract. IF -3,608

Jimenez-Fonseca, P; Hernandez, R; Custodio, A; Vaswani, AR; Canovas, MS; Bayona, RS; Lopez, CL; Diaz-Guardamino, IE; Visa, L; Orra, EB; Arias, D; Viudez, A; Carnicero, AM; Cerda, P; Ferrer, M; Barreto, JEL; Limon, ML; Macias, I; Felices, P. Prognostic effect of surgery of metastases in patients with advanced gastric cancer: Real-world data from the AGAMENON registry. ANNALS OF ONCOLOGY. 2017; 28():-.Meeting Abstract. IF -11,855

Lecumberri, B; Lopez, E; Coronado, M; Rodado, S; Castelo, B. Thyroid Metastasis as First Manifestation of a Colon Adenocarcinoma With KRAS Mutation Usefulness of F-18-FDG PET/CT. CLINICAL NUCLEAR MEDICINE. 2017; 42(10):795-797.Article. IF -4,563

Macias, I; Carmona-Bayonas, A; Ferrer, M; Hernandez, R; Custodio, A; Lacalle, A; Barreto, JEL; Diaz-Guardamino, IE; Visa, L; Orra, EB; Izquierdo, MM; Azkarate, A; Diaz, A; Viudez, A; Canovas, MS; Vaswani, AR; Longo, F; de Castro, EM; Plazas, JG; Fonseca, PJ. Anthracycline-based triplets do not improve the efficacy of platinumfluoropyrimidine doublets in advanced gastric cancer: AGAMENON study data. ANNALS OF ONCOLOGY. 2017; 28:-.Meeting Abstract. IF -11,855

Manos, M; Giralt, J; Rueda, A; Cabrera, J; Martinez-Trufero, J; Marruecos, J; Lopez-Pousa, A; Rodrigo, JP; Castelo, B; Martinez-Galan, J; Arias, F; Chaves, M; Herranz, JJ; Arrazubi, V; Baste, N; Castro, A; Mesia, R. Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1). ORAL ONCOLOGY. 2017; 70():58-64.Review. IF -4,794

Martin, M; Chacon, JI; Anton, A; Plazaola, A; Garcia-Martinez, E; Segui, MA; Sanchez-Rovira, P; Palacios, J; Calvo, L; Esteban, C; Espinosa, E; Barnadas, A; Batista, N; Guerrero, A; Munoz, M; Romio, E; Rodriguez-Martin, C; Caballero, R; Casas, MI; Rojo, F; Carrasco, E; Antolin, S. Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. ONCOLOGIST. 2017; 22(11):1301-1308.Article. IF - 4,962

Martin-Broto, J; Redondo, A; Valverde, C; Vaz, MA; Mora, J; del Muro, XG; Gutierrez, A; Tous, C; Carnero, A; Marcilla, D; Carranza, A; Sancho, P; Martinez-Trufero, J; Diaz-Beveridge, R; Cruz, J; Encinas, V; Taron, M; Moura, DS; Luna, P; Hindi, N; Lopez-Pousa, A. Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). ANNALS OF ONCOLOGY. 2017; 28(12):2994-2999.Article. IF -11,855

Martinez-Marin, V; Redondo, A; Heredia, V; Guerra, L; Miguel-Martin, M; Crespo, R; Hardisson, D; Feliu, J; Mendiola, M. Comparison of two-dimensional (2D)- and three-dimensional (3D)culture models as drug testing platforms in GIST: experience with axitinib in vitro. EUROPEAN JOURNAL OF CANCER. 2017; 72:S155-S155.Meeting Abstract. IF -6,029

Mendiola, M; Heredia-Soto, V; Herranz, J; Martin, R; Aunon, PZ; Castelo, B; Marin, AP; Miguel, M; Crespo, R; de Molina, AR; Hardisson, D; Espinosa, E; Redondo, A. Micro-RNA profile in advanced metastatic breast cancer as a predictive tool for response to bevacizumab-paclitaxel. ANNALS OF ONCOLOGY. 2017; 28:-.Meeting Abstract. IF - 11,855

Mestres, JA; IMolins, AB; Martinez, LC; Lopez-Muniz, JIC; Gil, EC; Ferre, AD; Berron, SD; Perez, YF; Mata, JG; Palomo, AG; Gregori, JG; Pardo, PG; Manas, JJI; Hernandez, AL; de Duenas, EM; Janez, NM; Murillo, SM; Bofill, JS; Aunon, PZ; Sanchez-Rovira, P. Defining the optimal sequence for the systemic treatment of metastatic breast cancer. CLINICAL & TRANSLATIONAL ONCOLOGY. 2017; 19(2):149-161.Article. IF -2,353

Orgaz, MS; Pessolani, TG; Kreilinger, JJP; Zamora, P; Alvarez, CM; Boto-de-los-Bueis, A. Orbital and conjunctival metastasis from lobular breast carcinoma. ORBIT-AN INTERNATIONAL JOURNAL ON ORBITAL DISORDERS AND FACIAL RECONSTRUCTIVE SURGERY. 2017; 36(4):197-200.Article. IF -NO TIENE

Pascual, T; Gamez-Pozo, A; Camara-Jurado, M; Manso, LM; Perez-Campos, A; Trilla, L; Fresno-Vara, JA; Ciruelos, EM. Differential expression of microRNAs (miRNAs) in HER2 negative breast cancer (BC). CANCER RESEARCH. 2017; 77:-.Meeting Abstract. IF -9,112

Pelaez-Garcia, A; Yebenes, L; Berjon, A; Angulo, A; Zamora, P; Sanchez-Mendez, JI; Espinosa, E; Redondo, A; Heredia-Soto, V; Mendiola, M; Feliu, J; Hardisson, D. Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer. PLOS ONE. 2017; 12(9):-e0183452.Article. IF -2,806

Pineda, E; Salud, A; Vila-Navarro, E; Safont, MJ; Llorente, B; Aparicio, J; Vera, R; Escudero, P; Casado, E; Bosch, C; Bohn, U; Perez-Carrion, R; Carmona, A; Ayuso, JR; Ripolles, T; Bouzas, R; Gironella, M; Garcia-Albeniz, X; Feliu, J; Maurel, J. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. TUMOR BIOLOGY. 2017; 39(6):-UNSP 1010428317705509.Article. IF -3,65

Pujade-Lauraine, E; Colombo, N; Glasspool, R; Asselain, B; Huzarski, T; Korach, J; Marme, F; Mirza, MR; Redondo, A; Scambia, G; Blakeley, C; Milner, A; Selle, F; Vergote, I. OReO/ENGOT Ov-38: A phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer. ANNALS OF ONCOLOGY. 2017; 28:-.Meeting Abstract. IF -11,855

Pulido, EG; Teule, A; Alonso-Gordoa, T; Jimenez-Fonseca, P; Benavent, M; Capdevila, J; Custodio, A; Vera, R; Munarriz, J; La Casta-Munoz, A; Garcia-Carbonero, R. A phase II trial of palbociclib in metastatic grade 1/2 pancreatic neuroendocrine tumors: The PALBONET study on behalf of the Spanish Taskforce Group of Neuroendocrine Tumors (GETNE). ANNALS OF ONCOLOGY. 2017; 28():-.Meeting Abstract. IF -11,855

Ramirez, SP; del Monte-Millan, M; Lopez-Tarruella, S; Marquez-Rodas, I; Jerez, Y; Samper, FL; Peron, YI; Janez, NM; Garcia-Saenz, JA; Anton, FM; Aunon, PZ; Yustos, MA; Alvarez, MAL; Gil, EMC; Sanchez, LM; Gonzalez, MJE; Martinez, JAG; Sanchez, CJ; Maganto, VV; Jimenez, MM. Distribution of genomically defined recurrence risk in luminal A and B breast tumors defined by immunohistochemistry: A retrospective study in Spanish population. ANNALS OF ONCOLOGY. 2017; 28:-.Meeting Abstract. IF -11,855

Redondo, A; Bague, S; Bernabeu, D; Ortiz-Cruz, E; Valverde, C; Alvarez, R; Martinez-Trufero, J; Lopez-Martin, JA; Correa, R; Cruz, J; Lopez-Pousa, A; Santos, A; del Muro, XG; Martin-Broto, J. Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2017; 80(6):1113-1131.Article. IF -2,737

Rodriguez-Salas, N; Dominguez, G; Barderas, R; Mendiola, M; Garcia-Albeniz, X; Maurel, J; Batlle, JF. Clinical relevance of colorectal cancer molecular subtypes. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2017; 109:9-19.Review. IF -4,971

Rojas, K; Trilla-Fuertes, L; Gamez, A; Sanchez, JS; Sanchez, LM; Prado-Vasquez, G; Chiva, C; Zapater-Moros, A; Llorente-Armijo, S; Mendiola, DC; Sabido, E; Fresno, JA; Gil, EMC; Paz-Ares, L. Proteomics of triple negative breast cancer developing metastases to central nervous system. ANNALS OF ONCOLOGY. 2017; 28:-.Meeting Abstract. IF - 11,855

Sanchez-Mendez, JI; Yebenes, L; Zamora, P; Marti, C; Pelaez-Garcia, A; Alonso, P; Berjon, A; de la Noval, BD; Espinosa, E; Hardisson, D. EndoPredict molecular-clinicopathological hybrid score (EPclin) provides superior prognostic information compared to molecular scores alone: a report of two cases. BREAST. 2017; 32:S104-S104.Meeting Abstract. IF -2,801

Sereno, M; Gutierrez-Gutierrez, G; Rubio, JM; Apellaniz-Ruiz, M; Sanchez-Barroso, L; Casado, E; Falagan, S; Lopez-Gomez, M; Merino, M; Gomez-Raposo, C; Rodriguez-Salas, N; Tebar, FZ; Rodriguez-Antona, C. Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy. BMC CANCER. 2017; 17:-63.Article. IF -3,288

Solis-Hernandez, MP; Calvo-Temprano, D; Carmona-Bayonas, A; Garcia-Carbonero, R; Custodio, A; Alonso, T; Matos, I; Benavent, M; Lopez, C; Canovas, MS; Viudez, A; Capdevila, J; Grande, E; Alonso, V; Jimenez-Fonseca, P. Clinical Features and Outcomes of Advanced PNETs Treated with Sunitinib: Data from CRIPNET-GETNE Study. NEUROENDOCRINOLOGY. 2017; 105:226-226.Meeting Abstract. IF -3,608

Solis-Hernandez, MP; Carmona-Bayonas, A; Calvo-Temprano, D; Nunez, B; Custodio, A; Alonso, T; Matos, I; Benavent, M; Lopez, C; Canovas, MS; Viudez, A; Garcia-Carbonero, R; Grande, E; Capdevila, J; Jimenez-Fonseca, P. Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study. NEUROENDOCRINOLOGY. 2017; 105:174-174.Meeting Abstract. IF -3,608

Soria, A; Manzano, JL; Berrocal, A; Espinosa, E; Marquez-Rodas, I; Gonzalez-Cao, M; Martin-Algarra, S. Highlights of the season 2016-2017 by the Spanish Melanoma Group (GEM). ANNALS OF TRANSLATIONAL MEDICINE. 2017; 5(19):-391.Article. IF -NO TIENE

Valdes-Mora, F; Locke, WJ; Bandres, E; Gallego-Ortega, D; Cejas, P; Garcia-Cabezas, MA; Colino-Sanguino, Y; Feliu, J; del Pulgar, T; Lacal, JC. Clinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer. ONCOTARGET. 2017; 8(16):26755-26770.Article. IF -5,168

Wang, J; Zhang, ZY; Mirza, MR; Gilbert, L; Fabbro, M; Tinker, AV; Wang, X; Redondo, A; Berek, JS; Woelber, L; Pentikis, HS; Moore, KN; Lorusso, D; Benigno, B; Hazard, SJ; Follana, P; Rimel, BJ; Matulonis, UA; Agarwal, S; Kansra, V. The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial. ANNALS OF ONCOLOGY. 2017; 28:-.Meeting Abstract. IF -11,855

N° Documentos	Tipo de documento	FI	1° Cuartil	1° Decil
32	Artículos	136,646	18	5
25	Meeting Abstract	239,637	21	17
6	Revisiones	19,697	3	1
	FI Originales	136,646		
	FI Total	395,98		